When did BRAINSTORM CELL THERAPEUTICS (BCLI) report earnings last quarter?
BRAINSTORM CELL THERAPEUTICS (BCLI) last reported earnings on 5/15/2025.
NASDAQ:BCLI • US10501E3009
Past quarterly earnings results for BRAINSTORM CELL THERAPEUTICS (BCLI), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2025 | -0.45 | -0.99 | 54.52% | 40.00% | - | - | ||
| Q4 2024 | -0.51 | -0.39 | -31.58% | -233.33% | - | - | ||
| Q3 2024 | -0.51 | -0.59 | 13.04% | -264.29% | - | - | ||
| Q2 2024 | -0.60 | -0.54 | -12.04% | 85.19% | - | - | ||
| Q1 2024 | -0.75 | -1.07 | 29.97% | 64.29% | - | - | ||
| Q4 2023 | -0.15 | - | 92.15% | - | - | |||
| Q3 2023 | -0.14 | -0.14 | 1.96% | 95.09% | - | - | ||
| Q2 2023 | -4.05 | -2.30 | -76.47% | -42.11% | - | - | ||
| Q1 2023 | -2.10 | -2.52 | 16.82% | 6.67% | - | - | ||
| Q4 2022 | -1.95 | -2.22 | 12.10% | 23.53% | - | - | ||
| Q3 2022 | -2.85 | -2.75 | -3.49% | -26.67% | - | - | ||
| Q2 2022 | -2.85 | -2.24 | -27.00% | -11.76% | - | - | ||
| Q1 2022 | -2.25 | -1.99 | -13.12% | 21.05% | - | - | ||
| Q4 2021 | -2.55 | -3.01 | 15.26% | 54.05% | - | - | ||
| Q3 2021 | -2.25 | -3.14 | 28.26% | -7.14% | - | - | ||
| Q2 2021 | -2.55 | -3.01 | 15.26% | 32.00% | - | - | ||
| Q1 2021 | -2.85 | -3.98 | 28.36% | 40.62% | - | - | ||
| Q4 2020 | -5.55 | -6.66 | 16.61% | - | - | - | ||
| Q3 2020 | -2.10 | -3.98 | 47.21% | - | - | - | ||
| Q2 2020 | -3.75 | -3.98 | 5.73% | - | - | - | ||
| Q1 2020 | -4.80 | -3.44 | -39.43% | - | - | - |
Notes
BRAINSTORM CELL THERAPEUTICS (BCLI) last reported earnings on 5/15/2025.
BRAINSTORM CELL THERAPEUTICS (BCLI) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, BRAINSTORM CELL THERAPEUTICS (BCLI) has beaten EPS estimates in 2 out of 4 releases.